Report cover image

Global Biosimilar Insulin Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 191 Pages
SKU # APRC20359402

Description

Summary

According to APO Research, the global Biosimilar Insulin market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Biosimilar Insulin is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Biosimilar Insulin is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Biosimilar Insulin market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Biosimilar Insulin is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Biosimilar Insulin market include Biocon, Geropharm, Wockhardt, Gan&Lee, Eli Lilly, United Laboratory, Sanofi and Tonghua Dongbao, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Biosimilar Insulin, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Biosimilar Insulin, also provides the sales of main regions and countries. Of the upcoming market potential for Biosimilar Insulin, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Biosimilar Insulin sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Biosimilar Insulin market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Biosimilar Insulin sales, projected growth trends, production technology, application and end-user industry.

Biosimilar Insulin Segment by Company

Biocon
Geropharm
Wockhardt
Gan&Lee
Eli Lilly
United Laboratory
Sanofi
Tonghua Dongbao
Biosimilar Insulin Segment by Type

Biosimilar Insulin Glargine
Biosimilar Insulin Lispro
Other
Biosimilar Insulin Segment by Application

Hospital
Retail Pharmacy
Others
Biosimilar Insulin Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Biosimilar Insulin status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Biosimilar Insulin market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Biosimilar Insulin significant trends, drivers, influence factors in global and regions.
6. To analyze Biosimilar Insulin competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilar Insulin market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biosimilar Insulin and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilar Insulin.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Biosimilar Insulin market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Biosimilar Insulin industry.
Chapter 3: Detailed analysis of Biosimilar Insulin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Biosimilar Insulin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Biosimilar Insulin in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Table of Contents

191 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Biosimilar Insulin Sales Value (2020-2031)
1.2.2 Global Biosimilar Insulin Sales Volume (2020-2031)
1.2.3 Global Biosimilar Insulin Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Biosimilar Insulin Market Dynamics
2.1 Biosimilar Insulin Industry Trends
2.2 Biosimilar Insulin Industry Drivers
2.3 Biosimilar Insulin Industry Opportunities and Challenges
2.4 Biosimilar Insulin Industry Restraints
3 Biosimilar Insulin Market by Company
3.1 Global Biosimilar Insulin Company Revenue Ranking in 2024
3.2 Global Biosimilar Insulin Revenue by Company (2020-2025)
3.3 Global Biosimilar Insulin Sales Volume by Company (2020-2025)
3.4 Global Biosimilar Insulin Average Price by Company (2020-2025)
3.5 Global Biosimilar Insulin Company Ranking (2023-2025)
3.6 Global Biosimilar Insulin Company Manufacturing Base and Headquarters
3.7 Global Biosimilar Insulin Company Product Type and Application
3.8 Global Biosimilar Insulin Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Biosimilar Insulin Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Biosimilar Insulin Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Biosimilar Insulin Market by Type
4.1 Biosimilar Insulin Type Introduction
4.1.1 Biosimilar Insulin Glargine
4.1.2 Biosimilar Insulin Lispro
4.1.3 Other
4.2 Global Biosimilar Insulin Sales Volume by Type
4.2.1 Global Biosimilar Insulin Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Biosimilar Insulin Sales Volume by Type (2020-2031)
4.2.3 Global Biosimilar Insulin Sales Volume Share by Type (2020-2031)
4.3 Global Biosimilar Insulin Sales Value by Type
4.3.1 Global Biosimilar Insulin Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Biosimilar Insulin Sales Value by Type (2020-2031)
4.3.3 Global Biosimilar Insulin Sales Value Share by Type (2020-2031)
5 Biosimilar Insulin Market by Application
5.1 Biosimilar Insulin Application Introduction
5.1.1 Hospital
5.1.2 Retail Pharmacy
5.1.3 Others
5.2 Global Biosimilar Insulin Sales Volume by Application
5.2.1 Global Biosimilar Insulin Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Biosimilar Insulin Sales Volume by Application (2020-2031)
5.2.3 Global Biosimilar Insulin Sales Volume Share by Application (2020-2031)
5.3 Global Biosimilar Insulin Sales Value by Application
5.3.1 Global Biosimilar Insulin Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Biosimilar Insulin Sales Value by Application (2020-2031)
5.3.3 Global Biosimilar Insulin Sales Value Share by Application (2020-2031)
6 Biosimilar Insulin Regional Sales and Value Analysis
6.1 Global Biosimilar Insulin Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Biosimilar Insulin Sales by Region (2020-2031)
6.2.1 Global Biosimilar Insulin Sales by Region: 2020-2025
6.2.2 Global Biosimilar Insulin Sales by Region (2026-2031)
6.3 Global Biosimilar Insulin Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Biosimilar Insulin Sales Value by Region (2020-2031)
6.4.1 Global Biosimilar Insulin Sales Value by Region: 2020-2025
6.4.2 Global Biosimilar Insulin Sales Value by Region (2026-2031)
6.5 Global Biosimilar Insulin Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Biosimilar Insulin Sales Value (2020-2031)
6.6.2 North America Biosimilar Insulin Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Biosimilar Insulin Sales Value (2020-2031)
6.7.2 Europe Biosimilar Insulin Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Biosimilar Insulin Sales Value (2020-2031)
6.8.2 Asia-Pacific Biosimilar Insulin Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Biosimilar Insulin Sales Value (2020-2031)
6.9.2 South America Biosimilar Insulin Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Biosimilar Insulin Sales Value (2020-2031)
6.10.2 Middle East & Africa Biosimilar Insulin Sales Value Share by Country, 2024 VS 2031
7 Biosimilar Insulin Country-level Sales and Value Analysis
7.1 Global Biosimilar Insulin Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Biosimilar Insulin Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Biosimilar Insulin Sales by Country (2020-2031)
7.3.1 Global Biosimilar Insulin Sales by Country (2020-2025)
7.3.2 Global Biosimilar Insulin Sales by Country (2026-2031)
7.4 Global Biosimilar Insulin Sales Value by Country (2020-2031)
7.4.1 Global Biosimilar Insulin Sales Value by Country (2020-2025)
7.4.2 Global Biosimilar Insulin Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Biosimilar Insulin Sales Value Growth Rate (2020-2031)
7.5.2 USA Biosimilar Insulin Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Biosimilar Insulin Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Biosimilar Insulin Sales Value Growth Rate (2020-2031)
7.6.2 Canada Biosimilar Insulin Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Biosimilar Insulin Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Biosimilar Insulin Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Biosimilar Insulin Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Biosimilar Insulin Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Biosimilar Insulin Sales Value Growth Rate (2020-2031)
7.8.2 Germany Biosimilar Insulin Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Biosimilar Insulin Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Biosimilar Insulin Sales Value Growth Rate (2020-2031)
7.9.2 France Biosimilar Insulin Sales Value Share by Type, 2024 VS 2031
7.9.3 France Biosimilar Insulin Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Biosimilar Insulin Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Biosimilar Insulin Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Biosimilar Insulin Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Biosimilar Insulin Sales Value Growth Rate (2020-2031)
7.11.2 Italy Biosimilar Insulin Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Biosimilar Insulin Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Biosimilar Insulin Sales Value Growth Rate (2020-2031)
7.12.2 Spain Biosimilar Insulin Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Biosimilar Insulin Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Biosimilar Insulin Sales Value Growth Rate (2020-2031)
7.13.2 Russia Biosimilar Insulin Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Biosimilar Insulin Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Biosimilar Insulin Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Biosimilar Insulin Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Biosimilar Insulin Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Biosimilar Insulin Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Biosimilar Insulin Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Biosimilar Insulin Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Biosimilar Insulin Sales Value Growth Rate (2020-2031)
7.16.2 China Biosimilar Insulin Sales Value Share by Type, 2024 VS 2031
7.16.3 China Biosimilar Insulin Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Biosimilar Insulin Sales Value Growth Rate (2020-2031)
7.17.2 Japan Biosimilar Insulin Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Biosimilar Insulin Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Biosimilar Insulin Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Biosimilar Insulin Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Biosimilar Insulin Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Biosimilar Insulin Sales Value Growth Rate (2020-2031)
7.19.2 India Biosimilar Insulin Sales Value Share by Type, 2024 VS 2031
7.19.3 India Biosimilar Insulin Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Biosimilar Insulin Sales Value Growth Rate (2020-2031)
7.20.2 Australia Biosimilar Insulin Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Biosimilar Insulin Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Biosimilar Insulin Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Biosimilar Insulin Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Biosimilar Insulin Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Biosimilar Insulin Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Biosimilar Insulin Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Biosimilar Insulin Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Biosimilar Insulin Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Biosimilar Insulin Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Biosimilar Insulin Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Biosimilar Insulin Sales Value Growth Rate (2020-2031)
7.24.2 Chile Biosimilar Insulin Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Biosimilar Insulin Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Biosimilar Insulin Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Biosimilar Insulin Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Biosimilar Insulin Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Biosimilar Insulin Sales Value Growth Rate (2020-2031)
7.26.2 Peru Biosimilar Insulin Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Biosimilar Insulin Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Biosimilar Insulin Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Biosimilar Insulin Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Biosimilar Insulin Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Biosimilar Insulin Sales Value Growth Rate (2020-2031)
7.28.2 Israel Biosimilar Insulin Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Biosimilar Insulin Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Biosimilar Insulin Sales Value Growth Rate (2020-2031)
7.29.2 UAE Biosimilar Insulin Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Biosimilar Insulin Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Biosimilar Insulin Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Biosimilar Insulin Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Biosimilar Insulin Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Biosimilar Insulin Sales Value Growth Rate (2020-2031)
7.31.2 Iran Biosimilar Insulin Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Biosimilar Insulin Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Biosimilar Insulin Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Biosimilar Insulin Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Biosimilar Insulin Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Biocon
8.1.1 Biocon Comapny Information
8.1.2 Biocon Business Overview
8.1.3 Biocon Biosimilar Insulin Sales, Value and Gross Margin (2020-2025)
8.1.4 Biocon Biosimilar Insulin Product Portfolio
8.1.5 Biocon Recent Developments
8.2 Geropharm
8.2.1 Geropharm Comapny Information
8.2.2 Geropharm Business Overview
8.2.3 Geropharm Biosimilar Insulin Sales, Value and Gross Margin (2020-2025)
8.2.4 Geropharm Biosimilar Insulin Product Portfolio
8.2.5 Geropharm Recent Developments
8.3 Wockhardt
8.3.1 Wockhardt Comapny Information
8.3.2 Wockhardt Business Overview
8.3.3 Wockhardt Biosimilar Insulin Sales, Value and Gross Margin (2020-2025)
8.3.4 Wockhardt Biosimilar Insulin Product Portfolio
8.3.5 Wockhardt Recent Developments
8.4 Gan&Lee
8.4.1 Gan&Lee Comapny Information
8.4.2 Gan&Lee Business Overview
8.4.3 Gan&Lee Biosimilar Insulin Sales, Value and Gross Margin (2020-2025)
8.4.4 Gan&Lee Biosimilar Insulin Product Portfolio
8.4.5 Gan&Lee Recent Developments
8.5 Eli Lilly
8.5.1 Eli Lilly Comapny Information
8.5.2 Eli Lilly Business Overview
8.5.3 Eli Lilly Biosimilar Insulin Sales, Value and Gross Margin (2020-2025)
8.5.4 Eli Lilly Biosimilar Insulin Product Portfolio
8.5.5 Eli Lilly Recent Developments
8.6 United Laboratory
8.6.1 United Laboratory Comapny Information
8.6.2 United Laboratory Business Overview
8.6.3 United Laboratory Biosimilar Insulin Sales, Value and Gross Margin (2020-2025)
8.6.4 United Laboratory Biosimilar Insulin Product Portfolio
8.6.5 United Laboratory Recent Developments
8.7 Sanofi
8.7.1 Sanofi Comapny Information
8.7.2 Sanofi Business Overview
8.7.3 Sanofi Biosimilar Insulin Sales, Value and Gross Margin (2020-2025)
8.7.4 Sanofi Biosimilar Insulin Product Portfolio
8.7.5 Sanofi Recent Developments
8.8 Tonghua Dongbao
8.8.1 Tonghua Dongbao Comapny Information
8.8.2 Tonghua Dongbao Business Overview
8.8.3 Tonghua Dongbao Biosimilar Insulin Sales, Value and Gross Margin (2020-2025)
8.8.4 Tonghua Dongbao Biosimilar Insulin Product Portfolio
8.8.5 Tonghua Dongbao Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Biosimilar Insulin Value Chain Analysis
9.1.1 Biosimilar Insulin Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Biosimilar Insulin Sales Mode & Process
9.2 Biosimilar Insulin Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Biosimilar Insulin Distributors
9.2.3 Biosimilar Insulin Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.